OAM
UTHR icon

Ostrum Asset Management’s United Therapeutics UTHR Stock Holding History

Ostrum Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.04M Buy
3,758
+170
+5% +$95.7K 0.1% 156
2026
Q1 		$2.13M Sell
3,588
-1,429
-28% -$712K 0.12% 137
2025
Q4 		$2.44M Sell
5,017
-797
-14% -$371K 0.12% 143
2025
Q3 		$2.44M Sell
5,814
-3,674
-39% -$1.24M 0.11% 168
2025
Q2 		$2.73M Sell
9,488
-56,129
-86% -$16.8M 0.13% 149
2025
Q1 		$20.2M Buy
65,617
+60,040
+1,077% +$20.6M 1.06% 21
2024
Q4 		$1.97M Buy
5,577
+2,727
+96% +$1M 0.17% 197
2024
Q3 		$1.02M Sell
2,850
-8,339
-75% -$2.82M 0.08% 305
2024
Q2 		$3.56M Sell
11,189
-6,688
-37% -$1.77M 0.31% 78
2024
Q1 		$4.11M Sell
17,877
-4,472
-20% -$1.01M 0.32% 76
2023
Q4 		$4.91M Sell
22,349
-6,484
-22% -$1.49M 0.43% 49
2023
Q3 		$6.51M Buy
28,833
+1,366
+5% +$315K 0.6% 19
2023
Q2 		$6.06M Sell
27,467
-1,853
-6% -$410K 0.51% 34
2023
Q1 		$6.57M Buy
+29,320
New +$7.23M 0.57% 23

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Ostrum Asset Management's UTHR Position: Q2 2026 in Review

Ostrum Asset Management increased its United Therapeutics (UTHR) stake by 4.7% in Q2 2026, buying an estimated $95.7K and bringing the position to 3,758 shares worth $2.04M. The position accounts for 0.1% of the portfolio, ranked #156.

Ostrum Asset Management first reported a position in UTHR in Q1 2023 and has held it in 14 quarters since. The position peaked at $20.2M in Q1 2025. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Ostrum Asset Management held 3,758 shares of United Therapeutics worth $2.04M as of Q2 2026.
  • Ostrum Asset Management bought 170 United Therapeutics shares in Q2 2026, an estimated $95.7K.
  • United Therapeutics made up 0.1% of Ostrum Asset Management's portfolio in Q2 2026, its #156 holding.
  • Ostrum Asset Management first reported a position in United Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Ostrum Asset Management's United Therapeutics position peaked at $20.2M in Q1 2025.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Ostrum Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.